EC Number   |
Natural Substrates |
|---|
    3.3.2.10 | (10R)-hydroxy-(11S,12S)-epoxy-(5Z,8Z,14Z)-eicosatrienoic acid + H2O |
i.e. hepoxilin B3 |
| 3.3.2.10 | (5Z,11Z,14Z)-8,9-epoxyeicosatrienoic acid + H2O |
- |
| 3.3.2.10 | (5Z,8Z,11Z)-14,15-epoxyeicosa-5,8,11-trienoic acid + H2O |
- |
| 3.3.2.10 | (5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O |
- |
| 3.3.2.10 | (5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O |
14,15-epoxyeicosatrienoic acid, i.e. 14,15-EET, is cytoprotective in vivo, which is in part mediated by STAT3, overview |
| 3.3.2.10 | (5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O |
EETs exhibit a wide array of potentially beneficial actions in stroke, including vasodilation, neuroprotection, promotion of angiogenesis and suppression of platelet aggregation, oxidative stress and postischemic inflammation |
| 3.3.2.10 | (5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O |
i.e. 14,15-EET, EETs have antiinflammatory effects and are required for normal endothelial function |
| 3.3.2.10 | (5Z,8Z,11Z)-14,15-epoxyeicosatrienoic acid + H2O |
i.e. EETs, showing endothelium-derived hyperpolarizing factor effects dominating in microvessels independent of nitric oxide and prostacyclin. sEH reduces the beneficial effects of EETs |
| 3.3.2.10 | (5Z,8Z,14Z)-11,12-epoxyeicosatrienoic acid + H2O |
- |
| 3.3.2.10 | (8R)-hydroxy-(11S,12S)-epoxy-(5Z,9E,14Z)-eicosatrienoic acid + H2O |
i.e. hepoxilin A3, hydrolysis in liver is mainly catalyzed by soluble epoxide hydrolase |
